132 related articles for article (PubMed ID: 34007719)
21. The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER).
Langley PC
Innov Pharm; 2020; 11(3):. PubMed ID: 34007634
[TBL] [Abstract][Full Text] [Related]
22. Na domhain shamhlaíochta: formulary submission guidelines in Ireland and the standards of normal science.
Langley PC
Curr Med Res Opin; 2016 Oct; 32(10):1641-1644. PubMed ID: 27181031
[TBL] [Abstract][Full Text] [Related]
23. More Unnecessary Imaginary Worlds - Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes.
Langley PC
Innov Pharm; 2020; 11(1):. PubMed ID: 34017637
[TBL] [Abstract][Full Text] [Related]
24. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.
Watkins JB; Minshall ME; Sullivan SD
J Manag Care Pharm; 2006; 12(9):726-35. PubMed ID: 17249905
[TBL] [Abstract][Full Text] [Related]
25. To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims.
Langley PC
Innov Pharm; 2020; 11(4):. PubMed ID: 34007652
[TBL] [Abstract][Full Text] [Related]
26. Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
[No Abstract] [Full Text] [Related]
27. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report.
Fry RN; Avey SG; Sullivan SD
Value Health; 2003; 6(5):505-21. PubMed ID: 14627057
[TBL] [Abstract][Full Text] [Related]
28. Why imaginary worlds? The psychological foundations and cultural evolution of fictions with imaginary worlds.
Dubourg E; Baumard N
Behav Brain Sci; 2021 Jul; 45():e276. PubMed ID: 34233768
[TBL] [Abstract][Full Text] [Related]
29. AMCP Partnership Forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval.
J Manag Care Spec Pharm; 2017 Jan; 23(1):105-112. PubMed ID: 28025919
[TBL] [Abstract][Full Text] [Related]
30. Evaluating the Presence of Cognitive Biases in Health Care Decision Making: A Survey of U.S. Formulary Decision Makers.
Mezzio DJ; Nguyen VB; Kiselica A; O'Day K
J Manag Care Spec Pharm; 2018 Nov; 24(11):1173-1183. PubMed ID: 30362919
[TBL] [Abstract][Full Text] [Related]
31. Blockchains, Property Rights and Health Technology Assessment in the Pharmaceutical and Device (s) Industries.
Langley PC; Martin RE
Innov Pharm; 2018; 9(4):. PubMed ID: 34007731
[TBL] [Abstract][Full Text] [Related]
32. Use of health-related quality of life information in managed care formulary decision-making.
Wu WK; Sause RB; Zacker C
Res Social Adm Pharm; 2005 Dec; 1(4):579-98. PubMed ID: 17138497
[TBL] [Abstract][Full Text] [Related]
33. Blockchain Integration With Digital Technology and the Future of Health Care Ecosystems: Systematic Review.
Fatoum H; Hanna S; Halamka JD; Sicker DC; Spangenberg P; Hashmi SK
J Med Internet Res; 2021 Nov; 23(11):e19846. PubMed ID: 34726603
[TBL] [Abstract][Full Text] [Related]
34. Measurement, modeling and QALYs.
Langley PC; McKenna SP
F1000Res; 2020; 9():1048. PubMed ID: 33093950
[TBL] [Abstract][Full Text] [Related]
35. Imaginary worlds are
Goldy SP; Piff PK
Behav Brain Sci; 2022 Nov; 45():e284. PubMed ID: 36396419
[TBL] [Abstract][Full Text] [Related]
36. AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan.
Spooner JJ; Gandhi PK; Connelly SB
J Manag Care Pharm; 2007; 13(1):37-43. PubMed ID: 17269835
[TBL] [Abstract][Full Text] [Related]
37. AMCP Partnership Forum: FDAMA Section 114-Improving the Exchange of Health Care Economic Data.
J Manag Care Spec Pharm; 2016 Jul; 22(7):826-31. PubMed ID: 27333323
[TBL] [Abstract][Full Text] [Related]
38. Validation of modeled pharmacoeconomic claims in formulary submissions.
Langley PC
J Med Econ; 2015; 18(12):993-9. PubMed ID: 26549802
[TBL] [Abstract][Full Text] [Related]
39. Nutrition and health technology assessment: when two worlds meet.
Poley MJ
Front Pharmacol; 2015; 6():232. PubMed ID: 26539116
[TBL] [Abstract][Full Text] [Related]
40. Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study.
Hung A; Slejko JF; Lugo A; Shaya F; Haines ST; Mullins CD
J Manag Care Spec Pharm; 2019 Aug; 25(8):913-921. PubMed ID: 31347981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
